
Maravai LifeSciences Holdings Inc (MRVI) Stock: A Look at the Analyst Recommendations
MRVI has 36-month beta value of 0.30. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,”
MRVI has 36-month beta value of 0.30. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,”
In the past week, MRVI stock has gone down by -7.98%, with a monthly decline of -34.47% and a quarterly plunge of -61.89%. The volatility
Moreover, the 36-month beta value for MRVI is 0.22. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1
The stock of Maravai LifeSciences Holdings Inc (MRVI) has gone down by -6.09% for the week, with a -28.48% drop in the past month and
The 36-month beta value for MRVI is at 0.13. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 1
The 36-month beta value for MRVI is at 0.13. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 1
Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) has seen a decline in its stock price by -2.27 in relation to its previous close of 2.64. However,
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.